Yohann Loriot, Arash Rezazadeh Kalebasty, Aude Fléchon, Rohit K Jain, Sumati Gupta, Manojkumar Bupathi, Philippe Beuzeboc, Phillip Palmbos, Arjun V Balar, Christos E Kyriakopoulos, Damien Pouessel, Cora N Sternberg, Julia Tonelli, Mitch Sierecki, Huafeng Zhou, Petros Grivas, Philippe Barthélémy, Rick Bangs, Scott T Tagawa
WHAT IS THIS SUMMARY ABOUT?: Sacituzumab govitecan (brand name: TRODELVY® ) is a new treatment being studied for people with a type of bladder cancer, called urothelial cancer, that has progressed to a locally advanced or metastatic stage. Locally advanced and metastatic urothelial cancer are usually treated with platinum-based chemotherapy. Metastatic urothelial cancer is also treated with immune checkpoint inhibitors. There are few treatment options for people whose cancer gets worse after receiving these treatments...
April 29, 2024: Future Oncology